NAVA lanserer nytt produkt i Norge


http://www.navamedic.com/no/nyheter/2019/08/navamedic-is-launching-alflorex-in-norway/

“We are pleased to announce that Navamedic is entering into the gastro therapeutic area through the first probiotic product with IBS as approved indication. Alflorex® for IBS is part of a strategic partnership with PrecisionBiotics Ltd., who is developing unique bacteria cultures that have been specifically researched and rigorously tested for specific indications,” says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.

Alflorex® for IBS is classified as a medical device and contains the patented bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is clinically proven to reduce symptoms of IBS, including bloating and gas, abdominal pain, diarrhoea and constipation. About 10-15% of the population have IBS symptoms affecting their quality of life. From September 2019, Alflorex® for IBS will be available in Norwegian pharmacies helping IBS sufferers to take back control of their gut health.

“Entering into the consumer health market with unique products is key to Navamedic's growth strategy. Both the consumer health gastro therapeutic area and the probiotic market is underdeveloped in the Nordics, and we aim to drive growth in this market with this unique product”, says Kathrine Gamborg Andreassen.

The 35624® bacterial strain was first launched in the US in 2007, and has since developed into a global market leader. Alflorex® is now available in Europe, already successfully launched in selected countries
Redigert 05.08.2019 kl 10:02 Du må logge inn for å svare
sjoen7
05.08.2019 kl 19:45 297

Ingen info om forventet omsetting.
inva
05.08.2019 kl 20:05 285

Gode nyheter dette, her legges det stadig vekk til nye produkter og dette er i salg allerede om 2 måneder.
Men, hvorfor ikke estimere det økonomiske potensialet i meldingene som sendes ut?. Jeg gjør et forsøk:

Hele 10-15% av befolkningen kan ha nytte av dette produktet. La oss anta at 1% av befolkningen kommer til å benytte dette produktet fast noen år etter lansering. Pris i apotek ca kr 300 for 30 tabletter/1 pr dag, eks mva = 240 minus 30% fortjeneste til apotek = kr 184/mnd i omsetning for Navamedic pr bruker.

Norge 1%, 53 000 X 184 X 12 = 117 024 000,-

Danmark 1%, 57 000 X 184 X 12 = 125 856 000,-
Island 1%, 3 300 X 184 X 12 = 7 286 400,-

Produktet blir tatt godt imot i Europa: https://www.alimentaryhealth.ie/news/2019/6/6/alflorex-voted-best-digestive-product-at-otc-and-product-retail-awards-2019

Mange usikkerhetsmomenter her, men potensialet er stort.
sjoen7
05.08.2019 kl 23:54 230

Dette ser veldig bra ut. Skal ikke mye til for å få en god omsetning.
I tillegg har vi Mysimba som øker hver måned. Tenker det ikke er lenge før vi runder 300 mill i årlig omsetting.